Evidence map›Paper›PMID 31557839›Full record

ArticleInternational journal of molecular sciences2019

Clinical and Genetic Factors Associated with Resistance to Treatment in Patients with Schizophrenia: A Case-Control Study.

Aline Hajj, Sahar Obeid, Saria Sahyoun, Chadia Haddad, Jocelyne Azar, Lydia Rabbaa Khabbaz, Souheil Hallit

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aline HajjLaboratory of Pharmacology, Clinical Pharmacy and Drug Quality Control, Faculty of Pharmacy, Pôle Technologie-Santé (PTS), Faculty of Pharmacy, Saint-Joseph University, Beirut 1107 2180, Lebanon. aline.hajj@usj.edu.lb.
Sahar ObeidFaculty of Philosophy and Human Sciences, Holy Spirit University (USEK), Jounieh, Lebanon. Saharobeid23@hotmail.com.
Saria SahyounFaculty of Pharmacy, Saint-Joseph University, Beirut 1107 2180, Lebanon. saria.sahyoun@gmail.com.
Chadia HaddadPsychiatric Hospital of the Cross, Jal Eddib 6096, Lebanon. Chadia_9@hotmail.com.ORCID 0000-0003-2413-2684
Jocelyne AzarPsychiatric Hospital of the Cross, Jal Eddib 6096, Lebanon. Jossiek@hotmail.com.
Lydia Rabbaa KhabbazLaboratory of Pharmacology, Clinical Pharmacy and Drug Quality Control, Faculty of Pharmacy, Pôle Technologie-Santé (PTS), Faculty of Pharmacy, Saint-Joseph University, Beirut 1107 2180, Lebanon. lydia.khabbaz@usj.edu.lb.
Souheil HallitINSPECT-LB: Institut National de Sante Publique, Epidemiologie Clinique et Toxicologie, Beirut 1107 2180, Lebanon. souheilhallit@hotmail.com.ORCID 0000-0001-6918-5689

Funding

undefined <span style="color:gray;font-size:10px;">undefined</span> NA
6 · The paper itself

Abstract

objectivesTo assess clinical and genetic factors affecting response to treatment in a sample of patients with schizophrenia (treatment-resistant patients versus treatment responders). We also aimed at examining if these factors are different when we consider two different resistance classifications (the positive and negative syndrome scale, PANSS and the brief psychiatric rating scale, BPRS). MATERIAL AND

methodsA case-control study included treatment-resistant patients and good responders. Patients were stratified in two groups based on the established criteria for treatment-resistant schizophrenia using BPRS and PANSS. The study was approved by the ethical committees (references: CEHDF1017; HPC-017-2017) and all patients/legal representatives gave their written consent. Clinical factors were assessed. DNA was obtained using a buccal swab and genotyping for

resultsSome discrepancies between the BPRS and PANSS definitions were noted in our study when assessing the patients' psychopathological symptoms and response to treatment. The multivariable analysis, taking the presence versus absence of treatment resistance as the dependent variable, showed that that family history of schizophrenia, university studies, time since the beginning of treatment and chlorpromazine equivalent dose as well as the

conclusionUncovering the clinical and genetic factors associated with resistance to treatment could help us better treat our schizophrenic patients in a concept of personalized medicine.

Indexed as

Schizophrenic PsychologyAdultAllelesAntipsychotic AgentsCase-Control StudiesDrug ResistanceEpistasis, GeneticFemaleGene FrequencyGenotypeHumansMaleMiddle AgedOdds RatioSchizophreniaAntipsychotic AgentsBPRSCOMTDRD2MTHFROPRM1PANSSresistanceresponse to treatmentschizophrenia

Identifiers

PMID31557839
PMCPMC6801865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.